The observational registry CaPSURE study reported that men with prostate cancer who were taking aspirin were less likely to die of prostate cancer than nonusers. This favourable effect seems to be stronger than that observed in a pooled analysis of randomized clinical trials of aspirin, and in other observational studies.
Key Points
-
In a follow-up study of patients with prostate cancer, aspirin was related to an appreciable decrease in prostate cancer mortality
-
This decrease has been related to a favourable action of aspirin on thrombosis
-
Observational studies suggest a modest decrease in prostate cancer risk among aspirin users
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Choe, K. S. et al. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J. Clin. Oncol. 30, 3540–3544 (2012).
Bambace, N. M. & Holmes, C. E. The platelet contribution to cancer progression. J. Thromb. Haemost. 9, 237–249 (2011).
Gay, L. J. & Felding-Habermann, B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 11, 123–134 (2011).
Camerer, E. et al. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104, 397–401 (2004).
Cuzick, J. et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 10, 501–507 (2009).
Rothwell, P. M. et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379, 1591–1601 (2012).
Thun, M. J., Henley, S. J. & Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl Cancer Inst. 94, 252–266 (2002).
Brown, J. R. & DuBois, R. N. COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol. 23, 2840–2255 (2005).
Bosetti, C., Rosato, V., Gallus, S. & La Vecchia, C. Aspirin and urologic cancer risk: an update. Nat. Rev. Urol. 9, 102–110 (2012).
Bosetti, C., Rosato, V., Gallus, S., Cuzick, J. & La Vecchia, C. Aspirin and cancer risk: a quantitative review to 2011. Ann. Oncol. 23, 1403–1415 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
La Vecchia, C., Bosetti, C. Aspirin and the risk of prostate cancer mortality. Nat Rev Clin Oncol 9, 616–617 (2012). https://doi.org/10.1038/nrclinonc.2012.182
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.182
This article is cited by
-
Aspirin use decreases the risk of prostate cancer recurrence after post-prostatectomy radiotherapy
Journal of Radiation Oncology (2015)
